Global Transarterial Chemoembolization (TACE) Market – Industry Trends and Forecast to 2031

Transarterial Chemoembolization (TACE) Market Analysis and Size

In the transarterial chemoembolization (TACE) market, neoadjuvant therapy refers to the use of TACE as a pre-surgical treatment for liver cancer. Administering TACE before surgery, physicians aim to shrink the tumor and improve the feasibility and success rate of subsequent surgical procedures, such as liver resection or transplantation. Neoadjuvant TACE can help to reduce tumor size, control tumor growth, and potentially increase the such aslihood of complete tumor removal during surgery. This approach underscores the role of TACE as a valuable tool in the comprehensive management of liver cancer, offering patients a chance for improved surgical outcomes and overall prognosis.

Global transarterial chemoembolization (TACE) market size was valued at USD 2.29 billion in 2023 and is projected to reach USD 4.32 billion by 2031, with a CAGR of 8.25% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation       

Market Definition

Transarterial chemoembolization (TACE) procedure is used to treat liver cancer. It involves injecting chemotherapy drugs directly into the blood vessels that supply the tumor, followed by the insertion of tiny particles to block these vessels, thereby cutting off the tumor's blood supply and delivering high doses of chemotherapy directly to the cancerous cells. TACE aims to shrink tumors, relieve symptoms, and potentially improve patient outcomes.

Transarterial Chemoembolization (TACE) Market Dynamics

Drivers                                                                                          

• High Demand of Transarterial Chemoembolization (TACE) due to Minimally Invasive Nature

Patients and healthcare providers are drawn to TACE due to its less invasive approach compared to traditional surgery, leading to reduced recovery times and hospital stays. This appeal translates into increased patient acceptance and satisfaction, driving the demand for TACE procedures. Moreover, the reduced risk of complications associated with minimally invasive techniques enhances the safety profile of TACE, making it an attractive option for a broader patient population. As a result, the growing preference for minimally invasive treatments propels the expansion of the TACE market, offering patients effective therapeutic options with fewer procedural risks and improved quality of life.

• Rapid Technological Advancements Enhances Precision of Procedures

Innovations in imaging techniques, such as cone-beam CT and MRI, allow for better visualization of tumors and surrounding vasculature, aiding in precise catheter placement and drug delivery. Moreover, advancements in catheter technology enable more accurate and controlled embolization of tumor-feeding vessels, reducing complications and improving outcomes. The development of novel embolic agents with improved characteristics, such as increased biocompatibility and prolonged drug release, further enhances the therapeutic efficacy of TACE. These technological advancements attract both patients and healthcare providers, fostering greater adoption of TACE and driving market growth.

Opportunities

• Growing Screening Programs Increases the Demand of Transarterial Chemoembolization (TACE)

Screening programs increase early detection rates, identifying liver tumors at earlier, more treatable stages. As a result, more patients become eligible candidates for TACE, boosting its demand and adoption. Early detection through screening programs also improves overall patient outcomes and survival rates. Moreover, increased awareness of liver cancer risk factors prompts more individuals to undergo screenings, expanding the pool of potential TACE recipients. Overall, the growth of screening initiatives enhances the market for TACE by identifying more patients who can benefit from this minimally invasive treatment option.

• High Demand for Transarterial Chemoembolization (TACE) due to Favorable Reimbursement Policies

When insurance providers or government healthcare systems offer reimbursement for TACE procedures, it encourages more patients to opt for this treatment, expanding the market demand. Moreover, healthcare facilities are more inclined to offer TACE services when they are adequately reimbursed, leading to increased accessibility and availability of the procedure. Favorable reimbursement also incentivizes healthcare providers to invest in advanced equipment and training, further enhancing the quality and uptake of TACE treatments. Overall, robust reimbursement policies play a pivotal role in fostering the widespread adoption of TACE and driving market growth in liver cancer treatment.

Restraints/Challenges

• High Risk of Complications Limits the Adoption of Transarterial Chemoembolization (TACE)

While TACE is generally considered safe, potential complications such as liver damage, post-embolization syndrome, and infection can occur, impacting patient outcomes and confidence in the procedure. These risks may lead to hesitation among both patients and healthcare providers in opting for TACE as a treatment option for liver cancer. Concerns about adverse events may also contribute to longer decision-making processes or alternative treatment choices, ultimately affecting the demand for TACE procedures and restraining market growth.

• Cost Considerations Hampers the Demand of Transarterial Chemoembolization (TACE)

Despite reimbursement policies, the expenses associated with TACE procedures, including the cost of chemotherapy drugs, imaging studies, hospitalization, and follow-up care, can be substantial. For patients, particularly those without adequate insurance coverage or in regions with high out-of-pocket expenses, the financial burden may deter them from pursuing TACE treatment. These cost constraints limit the adoption of TACE, particularly in healthcare systems with constrained budgets or limited resources, ultimately impacting market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In May 2023, Bristol-Myers Squibb initiated the CheckMate 74W trial, evaluating Nivolumab with Ipilimumab and Nivolumab alone in combination with Trans-Arterial ChemoEmbolization (TACE) for participants with intermediate stage liver cancer. Nivolumab and Ipilimumab are immunotherapy drugs that work by enhancing the body's immune response against cancer cells, while TACE is a localized treatment that combines chemotherapy and embolization to target liver tumors directly. This trial aims to assess the efficacy and safety of these treatment combinations, potentially offering new therapeutic options for individuals with this type of cancer

Transarterial Chemoembolization (TACE) Market Scope

The market is segmented on the basis of procedure type, product type, indication and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Procedure Type

• Conventional TACE
• DEB-TACE

Product Type

• Chemotherapeutic Agents
• Radiotherapeutic Agents
• Drug-eluting Particles

Indication

• Unresectable HCC
• Early-Stage HCC

End-User

• Hospitals and Clinics
• Cancer Research Centers

Transarterial Chemoembolization (TACE) Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, procedure type, product type, indication and end-user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to dominate the market, driven by rising awareness of hepatocellular carcinoma (HCC) and advancements in early diagnosis techniques. The region benefits from substantial research and development investments, further fueling market expansion. These factors collectively contribute to North America's prominence in TACE, reflecting a robust ecosystem for addressing liver cancer and fostering innovation in treatment modalities.

Asia-Pacific is expected to experience significant growth, driven by rising incidences of hepatocellular carcinoma (HCC) in the region. In Japan, hepatitis C continues to be a primary factor contributing to HCC cases, whereas in much of Asia, hepatitis B virus is the predominant cause. This distinction underscores regional variations in the etiology of liver cancer, shaping the demand for treatments and highlighting the importance of tailored healthcare strategies across different parts of Asia.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Transarterial Chemoembolization (TACE) Market Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Questex (U.S.)
• Siemens Healthcare GmbH (Germany)
• Intermountain Healthcare (U.S.)
• Provincial Health Services Authority (Canada)
• Cancer Research Institute (U.S.)
• Bellicum Pharmaceuticals Inc. (U.S.)
• Boston Scientific Corporation (U.S.)
• Hikma Pharmaceuticals PLC (Jordan)
• Isofol Medical AB (publ) (Sweden)
• Nippon Kayaku Co. Ltd. (Japan)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Sirtex SIR-Spheres Pty Ltd. (Australia)
• Spectrum Pharmaceuticals, Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Bayer AG (Germany)
• Hepion Pharmaceuticals (U.S.)
• Polaris Pharmaceuticals (U.S.)
• Chugai Pharmaceutical Co., Ltd. (Japan)
• Merck & Co., Inc. (U.S.)

SKU-58999